MG
BCRX icon

Michael Gelband’s BioCryst Pharmaceuticals BCRX Stock Holding History

Michael Gelband’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7.45M Buy
744,917
+554,859
+292% +$5.02M 0.05% 370
2026
Q1 		$1.81M Buy
+190,058
New +$1.48M 0.01% 817
2025
Q4 		– Sell
-364,457
Closed -$2.77M – 1545
2025
Q3 		$2.77M Buy
364,457
+153,617
+73% +$1.28M 0.03% 620
2025
Q2 		$1.89M Buy
210,840
+149,907
+246% +$1.4M 0.02% 768
2025
Q1 		$457K Buy
+60,933
New +$491K ﹤0.01% 1125
2024
Q2 		– Sell
-172,961
Closed -$879K – 1534
2024
Q1 		$879K Sell
172,961
-19,241
-10% -$108K 0.01% 988
2023
Q4 		$1.15M Sell
192,202
-557,851
-74% -$3.23M 0.01% 764
2023
Q3 		$5.31M Sell
750,053
-462,494
-38% -$3.32M 0.05% 359
2023
Q2 		$8.54M Sell
1,212,547
-9,134
-0.7% -$73.3K 0.07% 286
2023
Q1 		$10.2M Buy
1,221,681
+1,199,839
+5,493% +$11.6M 0.08% 275
2022
Q4 		$251K Sell
21,842
-687,443
-97% -$8.57M ﹤0.01% 1405
2022
Q3 		$8.94M Buy
709,285
+366
+0.1% +$4.71K 0.12% 234
2022
Q2 		$7.5M Buy
+708,919
New +$7.31M 0.09% 271
2022
Q1 		– Sell
-120,827
Closed -$1.67M – 2196
2021
Q4 		$1.67M Buy
120,827
+78,532
+186% +$1.04M 0.02% 837
2021
Q3 		$608K Sell
42,295
-79,308
-65% -$1.25M 0.01% 1277
2021
Q2 		$1.92M Buy
+121,603
New +$1.65M 0.02% 700
2020
Q3 		– Sell
-35,969
Closed -$171K – 1746
2020
Q2 		$171K Buy
+35,969
New +$144K ﹤0.01% 1546

Other funds holding BCRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

Michael Gelband's BCRX Position: Q2 2026 in Review

Michael Gelband increased its BioCryst Pharmaceuticals (BCRX) stake by 292% in Q2 2026, buying an estimated $5.02M and bringing the position to 744,917 shares worth $7.45M. The position accounts for 0.05% of the portfolio, ranked #370.

Michael Gelband first reported a position in BCRX in Q2 2020 and has held it in 17 quarters since. The position peaked at $10.2M in Q1 2023. 316 funds tracked by Wall St. Rank hold BCRX as of Q2 2026.

  • Michael Gelband held 744,917 shares of BioCryst Pharmaceuticals worth $7.45M as of Q2 2026.
  • Michael Gelband bought 554,859 BioCryst Pharmaceuticals shares in Q2 2026, an estimated $5.02M.
  • BioCryst Pharmaceuticals made up 0.05% of Michael Gelband's portfolio in Q2 2026, its #370 holding.
  • Michael Gelband first reported a position in BioCryst Pharmaceuticals in Q2 2020 and has held it in 17 quarters since.
  • Michael Gelband's BioCryst Pharmaceuticals position peaked at $10.2M in Q1 2023.
  • 316 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2026.

Based on ExodusPoint Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.